Evidence map›Paper›PMID 36690825›Full record

ArticleScientific reports2023

Macrophage numbers in the marginal area of sarcomas predict clinical prognosis.

Michinobu Umakoshi, Akiko Nakamura, Hiroyuki Tsuchie, Zhuo Li, Yukitsugu Kudo-Asabe, Ken Miyabe, Yukinobu Ito, Makoto Yoshida, Hiroyuki Nagasawa, Kyoji Okada and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Michinobu UmakoshiDepartment of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita, 010-8543, Japan. um.ak.2path@gmail.com.
Akiko NakamuraDepartment of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita, 010-8543, Japan.
Hiroyuki TsuchieDepartment of Orthopedic Surgery, Graduate School of Medicine, Akita University, Akita, Japan.
Zhuo LiDepartment of Laboratory Medicine, The First Affiliated Hospital of Xi'an Medical University, Xi'an, 710077, China.
Yukitsugu Kudo-AsabeDepartment of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita, 010-8543, Japan.
Ken MiyabeDepartment of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita, 010-8543, Japan.
Yukinobu ItoDepartment of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita, 010-8543, Japan.
Makoto YoshidaDepartment of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita, 010-8543, Japan.
Hiroyuki NagasawaDepartment of Orthopedic Surgery, Graduate School of Medicine, Akita University, Akita, Japan.
Kyoji OkadaDepartment of Physical Therapy, Graduate School of Health Science, Akita University, Akita, Japan.
Hiroshi NanjoDepartment of Pathology, Akita University Hospital, Akita, Japan.
Daichi MaedaDepartment of Molecular and Cellular Pathology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Naohisa MiyakoshiDepartment of Orthopedic Surgery, Graduate School of Medicine, Akita University, Akita, Japan.
Masamitsu TanakaDepartment of Molecular Medicine and Biochemistry, Graduate School of Medicine, Akita University, Akita, Japan.
Akiteru GotoDepartment of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita, 010-8543, Japan.
Akita University · JPAkita University Hospital · JPKanazawa University · JPXi'an Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Even when treated comprehensively by surgery, chemotherapy, and radiotherapy, soft-tissue sarcoma has an unfavorable outcome. Because soft-tissue sarcoma is rare, it is the subject of fewer clinicopathological studies, which are important for clarifying pathophysiology. Here, we examined tumor-associated macrophages in the intratumoral and marginal areas of sarcomas to increase our knowledge about the pathophysiology. Seventy-five sarcoma specimens (not limited to a single histological type), resected at our institution, were collected, and the number of CD68-, CD163-, and CD204-positive macrophages in the intratumoral and marginal areas was counted. We then performed statistical analysis to examine links between macrophage numbers, clinical factors, and outcomes. A high number of macrophages positive for all markers in both areas was associated with worse disease-free survival (DFS). Next, we divided cases according to the FNCLCC classification (Grade 1 and Grades 2/3). In the Grade 1 group, there was no significant association between macrophage number and DFS. However, in the Grade 2/3 group, high numbers of CD163- and CD204-positive macrophages in the marginal area were associated with poor DFS. By contrast, there was no significant difference between the groups with respect to high or low numbers of CD68-, CD163-, or CD204-positive macrophages in the intratumoral area. Multivariate analysis identified the number of CD163- and CD204-positive macrophages in the marginal area as an independent prognostic factor. Macrophage numbers in the marginal area of soft-tissue sarcoma may better reflect clinical behavior.

Indexed as

SarcomaSoft Tissue NeoplasmsAntigens, Differentiation, MyelomonocyticHumansMacrophagesPrognosisAntigens, Differentiation, Myelomonocytic

Identifiers

PMID36690825
PMCPMC9870999
OpenAlexW4317802721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.